(+48) 500 333 969, (+48) 502 318 888

Ginekologia i Położnictwo medical project
ISSN 1896-3315 e-ISSN 1898-0759

The High-risk Human Papilloma Virus (Hr-HPV) in Abnormal Pap Smears


Abstract

Author(s): Ihab I. Samaha, Ibrahim A. Abdelazim* and Tamer E. El-Ghazaly

Background: The Human papilloma virus (HPV) is the commonest sexually transmitted disease (STD) in low- and middle-income countries and it is the most powerful carcinogens implicated in cervical cancer.

Objectives: To detect types of Hr-HPV in abnormal Pap smears and cervical cytology abnormalities associated with Hr-HPV infection.

Methods: Women eligible for Pap smears and HPV-co-testing according to hospital protocol were included in this study. Pap smears were done using the liquid-based cytology (LBC) and evaluated according to the Bethesda system. HPV-DNA co-testing was done using the Anyplex-II. Collected data were statistically analyzed to detect types of Hr-HPV in abnormal Pap smears, and cervical cytology abnormalities associated with Hr-HPV infection.

Results: The prevalence of Hr-HPV in abnormal Pap smears was 48.2% (106/220). The Hr-HPV detected in abnormal Pap smears were HPV-16 (36.8% (39/106)), HPV-31 (12.3% (13/106)), HPV-58 (11.3% (12/106)), HPV-66 (10.4% (11/106)), HPV-51 (9.4% (10/106)), HPV-18 (7.5% (8/106)), while multiple Hr-HPVs-35, -33, -52, and 58 were detected in 12.3% (13/106) of abnormal Pap smears.
The Hr- HPV detected in 39.6% (42/106) of ASCUS, in 80.2% (85/106) of LSIL, in 81.1% (86/106) of ASC-H, and in 83.01 (88/106) of HSIL. The Hr-HPV detection rate was significantly higher in LSIL, ASC-H, and HSIL compared to ASCUS (P=0.002, 0.001 and 0.001, respectively).

Conclusion: The prevalence of Hr-HPV in abnormal Pap smears was 48.2%. The low prevalence of HPV-18 in this study confirms the variations in genotype distribution of Hr-HPV. The Hr-HPV detection rate was significantly higher in LSIL, ASC-H, and HSIL compared to ASCUS. This finding supports the recommendation of HPV co-testing with routine Pap smear in women aged 30-65 years.